Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas J. Schmidt is active.

Publication


Featured researches published by Thomas J. Schmidt.


Journal of Investigative Dermatology | 2009

Detection of Metabolites of Fumaric Acid Esters in Human Urine: Implications for Their Mode of Action

Martin Rostami-Yazdi; Bernd Clement; Thomas J. Schmidt; Daniel Schinor; Ulrich Mrowietz

Medvecz, Rachel Sajó, Réka Lepesi-Benk + o, Zsolt Tulassay, Mária Katona, Zsófia Hatvani, Antal Blazsek and Sarolta Kárpáti Semmelweis University, Department of Dermatology, Venerologie and Dermatooncology, Budapest, Hungary; Hungarian Academy of Sciences Semmelweis University Molecular Medicine Research Group, Budapest, Hungary and Szentágothai Regional Knowledge Centre, Semmelweis University, Budapest, Hungary E-mail: [email protected]


Phytochemistry | 2011

An unusual dimeric guaianolide with antiprotozoal activity and further sesquiterpene lactones from Eupatorium perfoliatum

Mareike Maas; Andreas Hensel; Fernando B. Da Costa; Reto Brun; Marcel Kaiser; Thomas J. Schmidt

The CH(2)Cl(2) extract of aerial parts of Eupatorium perfoliatum L. exhibits antiprotozoal activity under in vitro conditions, especially against Plasmodium falciparum (IC(50)=2.7μg/ml). The search for active compounds yielded seven sesquiterpene lactones: Four structurally similar guaianolides, one dimeric guaianolide, and two germacranolides. The guaianolides differ in the degree of oxidation at C-14, ranging from a hydroxyl group up to a free carboxylic acid. The dimeric guaianolide, structurally closely related to the monomers, displays an unusual type of interguaianolide linkage between C-14 and C-4. Except for the germacranolide euperfolitin, all STLs described here were hitherto unknown. Furthermore, the flavonoid aglycones eupafolin, hispidulin, patuletin, and kaempferol were identified in the extract, which, except for kaempferol, have not been described as constituents of E. perfoliatum before. The dimeric guaianolide was shown to be the most active constituent against Plasmodium falciparum (IC(50) = 2.0μM) and was less cytotoxic against rat skeletal myoblasts (IC(50) = 16.2μM, selectivity index of about 8).


European Journal of Medicinal Chemistry | 2013

Natural sesquiterpene lactones as inhibitors of Myb-dependent gene expression: structure-activity relationships.

Caroline Schomburg; Wolfgang Schuehly; Fernando B. Da Costa; Karl-Heinz Klempnauer; Thomas J. Schmidt

c-myb is a proto-oncogene encoding a transcription factor which is highly expressed in hematopoietic progenitor cells. It regulates the expression of genes important for lineage determination, cell proliferation, and differentiation. Deregulation of c-myb expression is known to be involved in the development of human tumors, especially certain types of leukemia and breast and colon cancer. The c-Myb protein has thus been identified as an interesting therapeutic target. We recently discovered that some sesquiterpene lactones suppress Myb-dependent gene expression which is a new mechanism for these natural products potential anti-cancer activity. We developed a test system to screen compounds for inhibitory activity on Myb-inducible reporter gene activation. Using this system we have now investigated 60 sesquiterpene lactones for their capacity to inhibit c-Myb-dependent gene activation. The IC50 values were in a range between 0.7 and >30 μM. The furanoheliangolide goyazensolide and the pseudoguaianolide helenalin acetate (IC50 = 0.6 and 0.7 μM, respectively) represent the most active inhibitors of c-Myb dependent gene expression found up to present. Control measurements for cell viability (MTS assay) proved that the observed activity on c-Myb dependent gene expression is not a function of cytotoxicity/unspecific cell damage. Structure-activity relationships were investigated by a QSAR approach based on flexible alignment of the most active compounds and a common pharmacophore model. These investigations resulted in a QSAR model which indicates that the potency of inhibitory activity on c-Myb-dependent transcription does not only depend on the presence of reactive Michael-acceptor features but also on their optimal spatial arrangement in the molecule.


Antimicrobial Agents and Chemotherapy | 2014

In Silico prediction and experimental evaluation of furanoheliangolide sesquiterpene lactones as potent agents against Trypanosoma brucei rhodesiense.

Thomas J. Schmidt; Fernando B. Da Costa; Norberto Peporine Lopes; Marcel Kaiser; Reto Brun

ABSTRACT As a continuation of our earlier study on the in vitro antiprotozoal activity of 40 natural sesquiterpene lactones (STLs), we extended the set of tested compounds from our laboratories to 59. On the basis of this extended data set, further enriched by literature data for 10 compounds tested under the same conditions, our quantitative structure-activity relationship (QSAR) analyses for activity against T. brucei rhodesiense (etiologic agent of human African trypanosomiasis, or sleeping sickness) were continued, and the QSAR model thus obtained with 69 structures was used to predict the activity of a virtual library of 1,750 STL structures. As a major result from these calculations, furanoheliangolide-type compounds, a subclass of STLs hitherto untested against T. brucei rhodesiense, were predicted to have an exceptionally high level of in vitro activity. Four representative compounds of this type, goyazensolide, 4,5-dihydro-2′,3′-epoxy-15-deoxygoyazensolide, budlein A, and 4,15-isoatriplicolide tiglate, were therefore tested. They displayed 50% inhibitory concentrations (IC50s) of 0.07, 0.20, 0.07, and 0.015 μM, respectively, so that the in silico prediction was experimentally confirmed. 4,15-Isoatriplicolide tiglate is the most potent STL against T. b. rhodesiense found. Furanoheliangolide STLs were thus identified as interesting leads against this parasite which deserve more detailed investigations.


Blood | 2016

Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction

Sagar Uttarkar; Emilie Dassé; Anna Coulibaly; Simone Steinmann; Anke Jakobs; Caroline Schomburg; Amke Trentmann; Joachim Jose; Peter Schlenke; Wolfgang E. Berdel; Thomas J. Schmidt; Carsten Müller-Tidow; Jonathan Frampton; Karl-Heinz Klempnauer

The transcription factor Myb plays a key role in the hematopoietic system and has been implicated in the development of leukemia and other human cancers. Inhibition of Myb is therefore emerging as a potential therapeutic strategy for these diseases. However, because of a lack of suitable inhibitors, the feasibility of therapeutic approaches based on Myb inhibition has not been explored. We have identified the triterpenoid Celastrol as a potent low-molecular-weight inhibitor of the interaction of Myb with its cooperation partner p300. We demonstrate that Celastrol suppresses the proliferative potential of acute myeloid leukemia (AML) cells while not affecting normal hematopoietic progenitor cells. Furthermore, Celastrol prolongs the survival of mice in a model of an aggressive AML. Overall, our work demonstrates the therapeutic potential of a small molecule inhibitor of the Myb/p300 interaction for the treatment of AML and provides a starting point for the further development of Myb-inhibitory compounds for the treatment of leukemia and, possibly, other tumors driven by deregulated Myb.


Leukemia | 2012

Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I.

Bujnicki T; Wilczek C; Caroline Schomburg; Feldmann F; Peter Schlenke; Carsten Müller-Tidow; Thomas J. Schmidt; Karl-Heinz Klempnauer

The c-myb proto-oncogene encodes a transcription factor that is highly expressed in the progenitor cells of the hematopoietic system, where it regulates the expression of genes important for lineage determination, cell proliferation and differentiation. There is strong evidence that deregulation of c-myb expression is involved in the development of human tumors, particularly of certain types of leukemia, and breast and colon cancer. The c-Myb protein is therefore an interesting therapeutic target. Here, we have investigated the potential of natural sesquiterpene lactones (STLs), a class of compounds that are active constituents of a variety of medicinal plants, to suppress Myb-dependent gene expression. We have developed a test system that allows screening of compounds for their ability to interfere with the activation of Myb target genes. Using this assay system, we have identified the STL mexicanin-I as the first cell-permeable, low-molecular-weight inhibitor of Myb-induced gene expression.


Molecules | 2014

Antiprotozoal Activity of Achillea ptarmica (Asteraceae) and Its Main Alkamide Constituents

Jb Althaus; Marcel Kaiser; Reto Brun; Thomas J. Schmidt

In the course of our ongoing screening of plants of the family Asteraceae for antiprotozoal activity, a CH2Cl2-extract from the flowering aerial parts of Achillea ptarmica L. (sneezewort yarrow) was found to be active in vitro against Trypanosoma brucei rhodesiense (IC50 = 0.67 µg/mL) and Plasmodium falciparum (IC50 = 6.6 μg/mL). Bioassay guided fractionation led to the isolation and identification of five alkamides from the most active fractions. Pellitorine and 8,9-Z-dehyropellitorine are the main components of the extract. Beside these olefinic acid amides, four alkamides with diene-diyne structures were isolated. All alkamides were tested for antiprotozoal activity in vitro. Pellitorine was the most active compound so far within this study against P. falciparum (IC50 = 3.3 µg/mL), while 8,9-Z-dehydropellitorine was most active against T. b. rhodesiense (IC50 = 2.0 µg/mL). The activity of pure pellitorine against Plasmodium is higher than that of the crude extract and thus explains the activity of the latter. None of the isolated alkamides, however, was as active against T. b. rhodesiense as the crude extract whose antitrypanosomal activity must therfore be due to a synergistic effect of the isolated compounds or to more active yet to be identified constituents.


PLOS ONE | 2014

Potential of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinones against Leishmania (L.) infantum: biological activity and structure-activity relationships.

Erika G. Pinto; Isabela O. Santos; Thomas J. Schmidt; Samanta Etel Treiger Borborema; Vitor F. Ferreira; David R. da Rocha; Andre G. Tempone

Naphtoquinones have been used as promising scaffolds for drug design studies against protozoan parasites. Considering the highly toxic and limited therapeutic arsenal, the global negligence with tropical diseases and the elevated prevalence of co-morbidities especially in developing countries, the parasitic diseases caused by various Leishmania species (leishmaniasis) became a significant public health threat in 98 countries. The aim of this work was the evaluation of antileishmanial in vitro potential of thirty-six 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinones obtained by a three component reaction of lawsone, the appropriate aldehyde and thiols adequately substituted, exploiting the in situ generation of o-quinonemethides (o-QM) via the Knoevenagel condensation. The antileishmanial activity of the naphthoquinone derivatives was evaluated against promastigotes and intracellular amastigotes of Leishmania (Leishmania) infantum and their cytotoxicity was verified in mammalian cells. Among the thirty-six compounds, twenty-seven were effective against promastigotes, with IC50 values ranging from 8 to 189 µM; fourteen compounds eliminated the intracellular amastigotes, with IC50 values ranging from 12 to 65 µM. The compounds containing the phenyl groups at R1 and R2 and with the fluorine substituent at the phenyl ring at R2, rendered the most promising activity, demonstrating a selectivity index higher than 15 against amastigotes. A QSAR (quantitative structure activity relationship) analysis yielded insights into general structural requirements for activity of most compounds in the series. Considering the in vitro antileishmanial potential of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinones and their structure-activity relationships, novel lead candidates could be exploited in future drug design studies for leishmaniasis.


Journal of Ethnopharmacology | 2011

Eupatorium perfoliatum L.: phytochemistry, traditional use and current applications.

Andreas Hensel; Mareike Maas; Jandirk Sendker; Matthias Lechtenberg; Frank Petereit; Alexandra Deters; Thomas J. Schmidt; Timo Stark

ETHNOPHARMACOLOGICAL RELEVANCEnEupatorium perfoliatum L. originates from North America, where it has been widely used since centuries by native Indians. Additionally extracts are used also in Europe as immunostimulating agent for treatment of fever and cold. The following review summarizes published data on phytochemistry, ethnopharmacological use, as well as clinical and preclinical data.nnnMATERIALS AND METHODSnLiterature survey was performed via SciFinder(®) on papers and patents and by systematic research in ethnopharmacological literature at various university libraries.nnnRESULTSnThe phytochemical composition of Eupatorium perfoliatum is described in detail for volatile oil, caffeic acid derivatives, flavonoids, sesquiterpene lactones, tannins, polysaccharides. Methods for analytical quality control, as well as specification for relevant lead structures can be deduced from published batch analysis. Preclinical studies indicate anti-inflammatory effects of ethanolic extracts, which can be correlated on a molecular level to eupafolin and sesquiterpen lactones. Antiplasmodial, antioxidative and immunomodulating activities are additionally discussed. Clinical data on the use of Eupatorium perfoliatum do not meet modern GCP requirements, but do indicate positive tendencies for use of ethanolic extracts for treatment of common colds.nnnCONCLUSIONnWhile the postulated immunostimulating properties of Eupatorium perfoliatum have not been confirmed by in vitro data, animal-studies and in vitro experiments with plant extracts both indicate antiinflammatory effects beside antiplasmodial effect against Plasmodium falciparum. Such an antiinflammation caused by the ethanolic extracts can be correlated well with clinical symptoms related to diseases as common cold, rheumatism, athritis etc. These data also support the plausibility of the plants traditional use by the North American indigenous population and early European settlers. In principle quality aspects of the herbal material have to be affirmed by establishing modern pharmacopoeial control methods to guarantee constant and reliable quality.


PLOS ONE | 2014

3-O-Galloylated Procyanidins from Rumex acetosa L. Inhibit the Attachment of Influenza A Virus

Andrea Derksen; Andreas Hensel; Wali Hafezi; Fabian Herrmann; Thomas J. Schmidt; Christina Ehrhardt; Stephan Ludwig; Joachim Kuhn

Infections by influenza A viruses (IAV) are a major health burden to mankind. The current antiviral arsenal against IAV is limited and novel drugs are urgently required. Medicinal plants are known as an abundant source for bioactive compounds, including antiviral agents. The aim of the present study was to characterize the anti-IAV potential of a proanthocyanidin-enriched extract derived from the aerial parts of Rumex acetosa (RA), and to identify active compounds of RA, their mode of action, and structural features conferring anti-IAV activity. In a modified MTT (MTTIAV) assay, RA was shown to inhibit growth of the IAV strain PR8 (H1N1) and a clinical isolate of IAV(H1N1)pdm09 with a half-maximal inhibitory concentration (IC50) of 2.5 µg/mL and 2.2 µg/mL, and a selectivity index (SI) (half-maximal cytotoxic concentration (CC50)/IC50)) of 32 and 36, respectively. At RA concentrations>1 µg/mL plaque formation of IAV(H1N1)pdm09 was abrogated. RA was also active against an oseltamivir-resistant isolate of IAV(H1N1)pdm09. TNF-α and EGF-induced signal transduction in A549 cells was not affected by RA. The dimeric proanthocyanidin epicatechin-3-O-gallate-(4β→8)-epicatechin-3′-O-gallate (procyanidin B2-di-gallate) was identified as the main active principle of RA (IC50 approx. 15 µM, SI≥13). RA and procyanidin B2-di-gallate blocked attachment of IAV and interfered with viral penetration at higher concentrations. Galloylation of the procyanidin core structure was shown to be a prerequisite for anti-IAV activity; o-trihydroxylation in the B-ring increased the anti-IAV activity. In silico docking studies indicated that procyanidin B2-di-gallate is able to interact with the receptor binding site of IAV(H1N1)pdm09 hemagglutinin (HA). In conclusion, the proanthocyanidin-enriched extract RA and its main active constituent procyanidin B2-di-gallate protect cells from IAV infection by inhibiting viral entry into the host cell. RA and procyanidin B2-di-gallate appear to be a promising expansion of the currently available anti-influenza agents.

Collaboration


Dive into the Thomas J. Schmidt's collaboration.

Top Co-Authors

Avatar

Marcel Kaiser

Swiss Tropical and Public Health Institute

View shared research outputs
Top Co-Authors

Avatar

Reto Brun

Swiss Tropical and Public Health Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge